Mydrane

Lidocaine hydrochloride monohydrate, the active ingredient in Mydrane, is a local anesthetic presented as an intracameral solution for intraocular use. It provides rapid anesthesia and, together with phenylephrine and tropicamide, produces pupil dilation during cataract surgery.\n\nGNH India supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mydrane is employed in ophthalmic surgery to achieve intraoperative pupil dilation and anesthesia.\n\nCataract surgery: provides rapid pupil dilation and intraocular anesthesia for safe lens removal.\nIntraocular lens implantation: ensures adequate pupil size for precise lens placement.\nAnterior segment procedures: facilitates mydriasis and analgesia during surgeries such as trabeculectomy or iridotomy.

Mydrane may cause a range of ocular and systemic reactions.\n\nCommon Side Effects:\n- Transient ocular pain or discomfort\n- Mild increase in intraocular pressure\n- Temporary blurred vision\n- Conjunctival hyperemia\n- Mild corneal edema\n- Headache\n\nSerious or Rare Side Effects:\n- Anaphylactic or severe allergic reaction\n- Sustained high intraocular pressure requiring intervention\n- Persistent mydriasis beyond the procedure\n- Corneal ulceration or keratitis\n- Endophthalmitis\n- Cardiovascular events such as hypertension or arrhythmia

Mydrane should be used with careful patient assessment and monitoring.\n\nAllergy assessment: confirm no hypersensitivity to lidocaine, phenylephrine, or tropicamide.\nIntraocular pressure monitoring: measure pressure before and after administration.\nGlaucoma caution: avoid in patients with narrow‑angle or uncontrolled glaucoma.\nCardiovascular risk: use cautiously in patients with hypertension or cardiac disease.\nSystemic drug interactions: review concurrent systemic adrenergic agents.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Mydrane can interact with other ophthalmic and systemic agents.\n\nMajor Interactions (Avoid):\n- Concurrent systemic phenylephrine with monoamine oxidase inhibitors: risk of hypertensive crisis.\n- Other potent mydriatics (e.g., apraclonidine): may cause excessive pupil dilation.\n- Additional local anesthetics: increased risk of lidocaine toxicity.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: may blunt intraocular pressure response.\n- Anticholinergic systemic drugs: additive mydriatic effect.\n- Antihypertensive agents: monitor blood pressure if systemic absorption occurs.